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Abstract
Purpose To formally test and validate a patient-reported
outcome measure (PROM) for patients with cardiac
arrhythmias undergoing catheter ablation procedures in the
UK [Cardiff Cardiac Ablation PROM (C-CAP)].
Methods A multicentre, prospective, observational cohort
study with consecutive patient enrolment from three UK
sites was conducted. Patients were sent C-CAP
questionnaires before and after an ablation procedure. Pre-
ablation C-CAP1 (17 items) comprised four domains:
patient expectations; condition and symptoms; restricted
activity and healthcare visits; medication and general
health. Post-ablation C-CAP2 (19 items) comprised five
domains including change in symptoms and procedural
complications. Both questionnaires also included the gen-
eric EQ-5D-5L tool (EuroQol). Reliability, validity, and
responsiveness measures were calculated.
Results A total of 517 valid pre-ablation and 434 post-
ablation responses were received; questionnaires showed
good feasibility and item acceptability. Internal consis-
tency was good (Cronbach’s alpha [0.7) and test–retest
reliability was acceptable for all scales. C-CAP scales
showed high responsiveness (effect size [0.8). Patients
improved significantly (p\ 0.001) following ablation
across all disease-specific and global scales. Minimal
clinically important difference was calculated. Improve-
ment beyond the smallest detectable change of 9 points
(symptom severity scale), 3 points (frequency and duration
of symptoms scale), and 8 points (impact on life scale)
indicates an important change. Amendments to the C-CAP
questionnaires were identified through the validation pro-
cess and made to produce the final tools.
Conclusions The final C-CAP questionnaires are valid,
reliable, and responsive tools for measuring symptom
change, impact, and expectations in patients undergoing
ablation for cardiac arrhythmias. C-CAP questionnaires
provide a tool with disease-specific and generic domains to
explore how cardiac ablation procedures in the UK impact
upon patients’ lives.
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Introduction
Cardiac arrhythmias are experienced by more than 1 million
people a year in the UK. Arrhythmia-related symptoms
include palpitations, breathlessness, chest pain, dizziness, and
fatigue [1], which can have profoundly negative effects on
patients’ quality of life (QoL) [2]. The cost to the UKNational
Health Service (NHS) of treating peoplewith atrial fibrillation
(AF), the most common of these arrhythmias, is large; esti-
mates put the direct cost at 0.9–2.4 % of overall healthcare
expenditure [3]. The intended benefit of percutaneous
radiofrequency cardiac ablation is to improve patient QoL and
eliminate or reduce arrhythmia-related symptoms.
Patient-reported outcome measures (PROMs) aim to
determine a patient’s own view of their symptoms, func-
tional status, and health-related QoL before and after an
intervention. PROMs offer a particularly useful platform to
evaluate the effect of cardiac ablation on arrhythmia-re-
lated symptoms because arguably the biggest impact of a
successful ablation treatment is an alleviation of anxiety
and physical symptoms [4].
Patient-reported outcome measures (PROMs) should
include both a generic and a disease-specific tool; both can be
used simultaneously to build a comprehensive picture of
patients’ status [5].Whilst genericQoL instruments such as SF-
36 and EQ-5D-5L have been validated and extensively used in
a variety of populations, formal validation of disease-specific
tools is not always often performed. Many QoL questionnaires
have been developed specifically for use in patientswithAF [4,
6]. The questionnaires validated in this study provide a method
of including both generic and disease-specific measures com-
binedwithmeasures of patient expectations and experiences of
their ablation procedure into one questionnaire.
The key elements of validation involve evaluating a PROM
tool for its reliability (test–retest, internal consistency), validity
(content and construct), sensitivity (to differences between
groups), and responsiveness (to change in patients’ condition)
[7]. These steps are essential to enable data derived from a tool
to be useful and interpretable. The aim of this study is to for-
mally validate a PROM tool for UK patients with arrhythmias
treated with catheter ablation. This builds on a previous feasi-
bility study [1] and the initial stage of this study which was to
establish content validity through patients’ interviews [8].
Methods
This multicentre, prospective, observational cohort study
was designed to formally develop, evaluate, and validate a
new UK PROM tool for patients with cardiac arrhythmias
treated with cardiac ablation procedures (UK Clinical
Research Network Study Portfolio reference 13148).
Ethics
The study protocol was reviewed and approved by the
Nottingham 1 Research Ethics Proportionate Review Sub-
Committee (reference 12/EM/0164) and conducted in
accordance with Good Clinical Practice and the Declara-
tion of Helsinki. Informed consent was obtained from all
patients who took part in this study.
Development of the initial C-CAP questionnaires
Initial item generation, face validity, and content validity
of the cardiac ablation PROM were evaluated as described
previously [1, 8]. The pre-validation C-CAP questionnaires
used in this study consist of a 17-item pre-ablation ques-
tionnaire (C-CAP1) and a 19-item post-ablation question-
naire (C-CAP2) and are described in full by Withers et al.
[8]. Questionnaires which incorporate the amendments
identified in the current validation study are termed ‘‘final
C-CAP1 and final C-CAP2’’ for clarity and have been
provided as an online resource.
Patients
Patients under the care of physicians at three clinical sites
in the UK (University Hospital Wales, Cardiff; Queen
Elizabeth Hospital, Birmingham; Freeman Hospital, New-
castle-Upon-Tyne) were eligible for inclusion in this study.
Patients were enrolled only if they were aged 18 or over,
had a diagnosis of symptomatic cardiac arrhythmia, had
consented to and were awaiting a cardiac ablation proce-
dure, and were able to read, write, and understand English
or Welsh.
Questionnaire procedures
Patients across three sites were approached consecutively
to take part in the study and provided with a participant
information sheet, consent form, the pre-validation, pre-
ablation questionnaire (C-CAP1), and a stamped addressed
envelope at the time of their appointment or with their
appointment letter. Patients were given time to consider
their involvement and completed the C-CAP1 question-
naire if and when they wished to do so (some completed
the questionnaire on the day of their ablation). Patients
from whom a signed consent form was received were
considered to be enrolled. Returned C-CAP1 question-
naires were excluded from analysis if the patient had
received their ablation procedure prior to completion of the
questionnaire.
No change in treatment or clinical assessment was car-
ried out on patients as a result of their participation in this
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study. Patients underwent percutaneous radiofrequency or
cryotherapy ablation using conscious sedation or a general
anaesthetic.
At 8–16 weeks following their ablation, patients were
sent a pre-validation, post-ablation questionnaire (C-
CAP2) to their home with a freepost envelope. Non-re-
sponders were sent a reminder letter with a replacement
questionnaire approximately 2–3 weeks after the initial
mailing. C-CAP2 questionnaires were excluded from
analysis if they were completed more than 20 weeks after
the ablation.
Identical retest questionnaires (C-CAP1R and
C-CAP2R) were sent to a random subset of patients (no
patients were sent retest questionnaires for both). Pre-ab-
lation retest questionnaires (C-CAP1R) were sent 1 week
after completion of C-CAP1. The following exclusions
were applied to select for patients who were assumed to
have a stable condition between completing test and retest
questionnaires: (1) an ablation was carried out in between
completion of C-CAP1 and C-CAP1R; (2) [30 days
elapsed between the patient completing C-CAP1 and
C-CAP1R. Post-ablation retest questionnaires (C-CAP2R)
were sent to patients 1 week after completion of C-CAP2.
Returned C-CAP2R questionnaires were excluded if
[30 days passed between completion of C-CAP2 and
C-CAP2R.
Further follow-up is currently being conducted at 1 and
5 years post-procedure (data not included in this
publication).
Sample size
No formal sample size calculation was conducted for this
questionnaire validation study. A minimum sample size of
150 patients from each centre has been suggested in pre-
vious studies to allow meaningful comparisons to be made
[9]. A target of 450 enrolled patients was set to ensure that
smaller sub-groups are adequately represented within the
sample and to provide representation from various
arrhythmia types.
Description of C-CAP questionnaires
Pre-validation C-CAP1 was split into four domains
(Table 1) and comprised 17 questions related to patient
expectations; condition and symptoms; activity and
healthcare visits; and medication and general health. The
conditions and symptoms domain contained three multi-
item scales: (1) symptom severity (15 sub-items); (2) fre-
quency and duration of symptoms (2 sub-items); (3) impact
on life (10 sub-items). Pre-validation C-CAP2 comprised
five domains (Table 1), three of which are replicated from
C-CAP1 and allowed comparison before and after the
procedure (condition and symptoms; activity and health-
care visits; and medication and general health). In addition
C-CAP2 covered change in symptoms and procedure-re-
lated symptoms. Both questionnaires also include the
generic EuroqoL EQ-5D-5L [10] questionnaire and visual
analogue scale (EQ-VAS). The EQ-5D-5L, used since the
beginning of this project, was chosen over the EQ-5D-3L
(used in other NHS PROM tools) because of its improved
discriminatory power which we felt was important during
development and testing of these questionnaires [11].
Data management and statistics
Patients completed the C-CAP questionnaires by hand in
their own time, and responses were entered by researchers
at Cedar Healthcare Technology Research Centre within
the UK NHS (Cardiff and Vale University Health Board)
into the National Audit of Cardiac Rhythm Management
(NACRM) database administered by National Institute for
Cardiovascular Outcomes Research (NICOR) at University
College London. All data entered onto the database were
checked for accuracy by a second researcher. Missing data
were not imputed. Data were exported from NACRM and
were analysed using IBM SPSS Statistics version 21. All
statistical tests were two-sided, and p values less than 0.05
were considered statistically significant.
Validation of C-CAP instrument
Feasibility and acceptability
Feasibility was assessed as the proportion of patients who,
following enrolment, returned questionnaires within the
required timeframe. Acceptability of individual items and
multi-item scales was assessed by patient response rate and
missing data. Ceiling and floor effects were evaluated as
the proportion of patients who responded with the mini-
mum and maximum scores for each dimension.
Reliability
Cronbach’s alpha was used to assess internal consistency
for disease-specific multi-item scales in C-CAP1 and
C-CAP2 (those with B2 items were excluded). Coefficients
above 0.7 were acceptable, 0.8 (good), and 0.9 (excellent)
[12].
Intraclass correlation coefficient (ICC) was used to
evaluate test–retest reliability. Scales with an ICC of C0.7
were considered to have good reliability. Bland–Altman
plots [13] were produced for multi-item scales. For binary
items, repeatability was assessed using the kappa coeffi-
cient (j) [7].
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Pre-validation, pre-ablation questionnaire (C-CAP1)
Pre-ablation patient
expectations
1–5 Contains a 4 item Likert scale (Q1–3b) with five response options (each item scored 0–4);
each explored patients’ treatment expectations prior to the procedure. The ‘‘treatment
expectations’’ multi-item scale had a minimum score of 0 and a maximum of 16 (the 4 items
in the scale were given equal weight, and each had a minimum score of 0 and a maximum of
4). This domain also asked whether this is the patient’s first ablation (Q4) and for the
number of previous ablations received (Q5)
Condition and symptoms 6, 7, 8, 13 This domain was a modified version of the disease-specific Patient Perception of Arrhythmia
Questionnaire (PPAQ) originally developed by Wood et al. [21]. Following adaptations for
use in a UK population with specialist, lay and patient input, this updated tool included
elements which were divided into three multi-item scales where a high score reflects a worse
health state:
Symptom severity (Q6a–o): 15 item symptom scale, each symptom/item had 4 response
options (scored 0–3). The minimum score was 0 and the maximum was 45 (equal weight
was given to each item in the scale and all subsequent scales)
Frequency and duration of symptoms (Q7–8): two item scale, each item had 5 response
options (scored 0–4). The minimum score was 0 and the maximum was 8
Impact on life (Q13a–j): 10 item scale, each item had 4 response options (scored 0–3). The
minimum score was 0 and the maximum score was 30
Restricted activity days and
healthcare visits
9a–12b This domain was modified from the PPAQ [20] and aimed to count how many days (either
work/school/college, social activities, or normal daily activities) in the last 30 have been
affected by arrhythmia symptoms. The number of visits to a GP or hospital in the last
30 days was also recorded
Medication and general
health
14–17 Q14 asked whether the respondent normally takes medication (yes/no); Q15 asked for the
name and dose of medication (free text); Q16 asked how important a reduction in
medication is for the respondent (Likert scale with 4 response categories scored from 0 to 3);
Q17 asked whether the respondent had been diagnosed with any one of a list of 12 common
conditions (with a ‘‘tick all that apply’’ instruction)
EQ-5D-5L Not numbered This comprised the widely used global health questionnaire which provides a simple
descriptive profile and a single index value for health status [10]. The EQ-5D-5L
questionnaire consists of five questions related to mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression. Each question can be answered on five different levels.
The EQ-5D-5L also includes a visual analogue scale (question 19) from 0 (worst health
imaginable) to 100 (best health imaginable). Therefore, a higher score is related to a better
outcome, in contrast to the other scoring systems used elsewhere in this paper
Pre-validation post-ablation questionnaire (C-CAP2)
Post-ablation change in
symptoms
1–3b, 7 This domain consists of 4 items each with 4 available responses relating to changes in
patients’ arrhythmia-related symptoms since receiving a procedure to treat their condition
(scored from 1 to 4 for each scale). Therefore, the change in symptoms multi-item scale has
a minimum score of 0 and a maximum of 16. This domain also asks whether the outcome of
the procedure met the patients’ expectations
Procedure-related
complications
4–6 This domain comprised a binary question relating to whether patients experienced any
ablation-related complications and two tables asking patients whether they were warned of
or experienced any of a list of complications
Condition and symptoms 8, 9, 10, 15 As described for C-CAP1
Restricted activity days and
healthcare visits
11a–13b As described for C-CAP1
Medication and general
health
16–19 As described for C-CAP1
EQ-5D-5L Not numbered As described for C-CAP1
C-CAP, Cardiff Cardiac Ablation PROM (patient-reported outcome measure); PPAQ, Patient Perception of Arrhythmia Questionnaire
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Validity
Content validity was evaluated using one-to-one cognitive
interviewing of patients as described by Withers et al. [8].
Convergent validity was tested by comparing the multi-
item scales in the condition and symptoms domain
(symptom severity; frequency and duration of symptoms;
impact on life) to validated global health scores (EQ-5D-
5L index and EQ-VAS scale). Correlation coefficients of
0.4–0.7 [Spearman’s Rho (q)] are considered moderate.
We expected that correlations between disease-specific
multi-item scales within C-CAP questionnaires would be
higher than the correlation between C-CAP scales and
global health scores. Discriminant validity was tested by
comparing scales in C-CAP questionnaires relating to
symptoms and impact against a multi-item scale relating to
patient expectations of the results of the procedure. It was
assumed that these domains measure different concepts and
therefore low correlations (\0.4) were expected.
Responsiveness and minimal clinically important
difference (MCID)
Several distribution-based methods [effect size (ES),
standardised response mean (SRM), relative efficiency
(RE)] were used to evaluate changes in C-CAP scores
following ablation. For both ES and SRM, values of 0.20,
0.50, and 0.80 represent the limits of small, moderate, and
large change, respectively [14].
Standard error of measurement (SEM) is a measure of
the precision of the instrument. The smallest
detectable change (SDC) was calculated from the SEM; it
reflects the smallest within-person change in score
(p\ 0.05) that can be interpreted as a real change above
measurement error [15] SDC = 1.96*H2*SEM.
Minimal clinically important difference (MCID) is
defined as the smallest difference in score in the domain of
interest which patients perceive as beneficial [16]. Four
anchor questions were used to estimate MCID in the case
of C-CAP: patients who reported that their symptoms
became less frequent; those who reported that the duration
of their arrhythmia episodes became shorter; patients
whose expectations were met; or patients who reported a
global health score improvement of 20 points were con-
sidered appropriate to show minimal important change.
Results
Questionnaire feasibility
Between March 2013 and August 2014 approximately 2200
eligible patients were invited to take part in the study
(estimated based on the number of questionnaire packs
supplied to clinical teams). Of these, 561 completed pre-
validation C-CAP1 questionnaires, of which 517 were valid
(Fig. 1). Respondents were 56 % male, with a mean age of
60 years [standard deviation (SD) 13]. The majority of
participants were treated for AF (47 %), and 22 % of
patients had undergone previous catheter ablations
(Table 2). A total of 437 valid pre-validation C-CAP2 (post-
ablation) questionnaires were returned (Fig. 1) and 434
patients returned both valid C-CAP1 and C-CAP2 ques-
tionnaires. There was a mean of 49 days [SD 52; median 36;
interquartile range (IQR) 7–82] between completion of the
C-CAP1 questionnaire and the ablation procedure, and then
a mean of 77 days (SD 16; median 72; IQR 65–83) between
the procedure and completion of C-CAP2. We did not
compare patients who were approached by clinicians to
those who were eventually enrolled. Consent was given once
patients returned their C-CAP1 questionnaire, and therefore,
we would not be able to analyse the records of patients who
did not return a questionnaire.
Item acceptability
The pre- and post-ablation symptom severity scale had a
response rate of 83.8 % (433 patients of 517) and 83.3 %
(364 of 437 patients), respectively. The pre- and post-ab-
lation impact on life scale had a response rate of 93.4 %
(483 patients of 517) and 90.4 % (395 patients of 437),
respectively (Table 3). Individual items within these
C-CAP1 and C-CAP2 multi-item scales had at least 90 %
response rate.
High patient numbers reported ‘‘not applicable’’ to
questions relating to number of days that symptoms have
impacted upon activities (Table 3). We considered N/A a
valid response for ‘‘days you have missed at work/
school/college’’ (i.e. for patients who are retired or unem-
ployed), but not for questions relating to ‘‘social activities’’
and ‘‘normal daily activities’’.
There was a high proportion of missing data for ques-
tions relating to medication expectations (Table 3) which
was almost entirely accounted for by patients responding to
an earlier question that they do not normally take medi-
cation for their palpitations.
The free text questions relating to medication name and
dosage presented difficulties in interpretation. There was
variation in how patients described both the name (i.e.
generic, brand, descriptive) and dose (strength, number of
tablets) which made consistent data entry less reliable.
Ceiling and floor effects
Ceiling effects of[15 % of respondents reporting maxi-
mum scores in multi-items scales were observed in both
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pre- and post-ablation EQ-5D-5L index scores (Table 3).
Also, 43 % of patients reported the minimum score in
frequency and duration of symptoms (corresponding to
‘‘never’’ for frequency and ‘‘not applicable’’ for duration in
combination) in the post-ablation questionnaire. No other
multi-item scales in C-CAP1 and C-CAP2 showed prob-
lematic ceiling and floor effects.
Internal consistency
The internal consistency of the items within three disease-
specific multi-item scales measured using Cronbach’s
alpha was acceptable for both pre- and post-ablation
questionnaires (Table 4). Item-total correlation suggested
good correlation of each item to the overall score, except in
the pre-ablation symptom severity scale whereby ‘‘passing
out/fainting/blackouts’’ fitted less well (item-total correla-
tion of 0.135; Table 4). Removal of this item improved the
overall Cronbach’s alpha. In the case of both the pre- and
post-ablation impact on life scale, removal of the item
relating to the financial impact of patient’s palpitations
improved overall Cronbach’s alpha (Table 4).
Test–retest reliability
Test–retest reliability was good (ICC C 0.7) for all dis-
ease-specific C-CAP scales: patient expectations (C-CAP1
only), symptom change (C-CAP2 only), symptom severity;
frequency and duration of symptoms; and impact on life,
except the pre-ablation frequency and duration scale (ICC
0.661). C-CAP scales had similar test–retest reliability to
EQ-5D-5L and EQ-VAS (Table 4). Of the individual items
within the pre-ablation multi-item scales, 23 of 41 had
ICCs of C0.7. Bland–Altman plots (12) did not indicate
bias between test and retest scores, and there was no sta-
tistically significant difference between the bias value and
0 (all p values[0.05; Table 4).
The kappa statistic (j) and the proportion of agreement
indicated moderate or high agreement between test and
retest responses for binary items. The highest was
j = 0.969 for ‘‘Is this your first ablation procedure?’’
(n = 82; p\ 0.0001; 99 % agreement), and the lowest was
j = 0.614 for ‘‘During your hospital stay, or in the month
afterwards, did you experience any complications related
to your ablation procedure?’’ (n = 79; p\ 0.0001; 87 %
agreement).
Approximately 2,200 patients invited to take part
561 CCAP1 returns
517 valid CCAP1 returns
• 41 excluded because 
patient completed CCAP1 
after the procedure




88 valid CCAP1R returns
499 CCAP2 sent
437 valid CCAP2 returns
147 CCAP2R sent
104 CCAP2R returns
88 valid CCAP2R returns
446 CCAP2 returns
• 6 excluded because 
procedure was prior to 
CCAP1 completion
• 29 excluded because 
procedure carried out in 
between CCAP1 and 
CCAP1R completion
• 15 invalid because >30 
days between CCAP1 
and CCAP1R completion 
• 3 excluded 
because returned 
CCAP2 was blank
• 6 excluded 




• 16 excluded 





434 patients with valid CCAD1 and CCAD2
Fig. 1 Patient response numbers to Cardiff Cardiac Ablation PROM (C-CAP) questionnaires
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Construct validity
Convergent and divergent validity
Convergent validity was confirmed by the observation of
moderate correlations [Spearman’s q (rho) of between 0.4
and 0.7] for three C-CAP disease-specific multi-item scales
from the conditions and symptoms domain shared by
C-CAP1 and C-CAP2 (symptom severity; frequency and
duration of symptoms; impact on life) against the validated
EQ-5D-5L and EQ-VAS tools assumed to be measuring
similar concepts. The exception was a mild correlation
between EQ-5D-5L/EQ-VAS and pre-ablation ‘‘frequency
and duration of symptoms’’ (q = -0.228 for EQ-5D-5L;
q = -0.221 for EQ-VAS). Correlations between symp-
tom-related multi-item scales within C-CAP were moder-
ate to high (q C 0.66).
Divergent validity was identified by the observation that
disease-related scales in C-CAP1 and C-CAP2 showed low
correlation with the ‘‘treatment expectation’’ scale which is
measuring a different underlying construct (all were
q\ 0.4).
Responsiveness
Changes from baseline to post-ablation in three disease-
specific C-CAP1 and C-CAP2 multi-item scales (symptom
severity; frequency and duration of symptoms; impact on
life) showed high responsiveness (ES and SRM [0.78;
Table 5). Patients reported a 43 % mean improvement in
the ‘‘symptom severity’’ scale (a change of -6.6 from a
baseline of 15.5; p\ 0.001), a 45 % improvement in the
‘‘symptom frequency and duration’’ scale (p\ 0.001), and
a 48 % improvement in the ‘‘impact on life’’ scale
(p\ 0.001). General QoL measures showed much smaller
ES and SRM values (Table 5). The relative efficiency (RE)
value also supports the finding that C-CAP questionnaires
are more sensitive than the global measures.
The MCIDs across four anchor questions are shown in
Table 5 and demonstrate consistency across the anchors. In
the case of the three disease-specificmulti-itemC-CAP scales
(shared across C-CAP1 and C-CAP2), the SEM was consid-
erably smaller than the anchor-based measures of MCID.
The SDC and limits of agreement in the Bland–Altman
plot (Table 4) were higher than the anchor-based estimate
Table 2 Demographics of enrolled patients and those with valid C-CAP1 and C-CAP2 questionnaires
Demographic Enrolled patients (n = 517) Patients with valid C-CAP1
and C-CAP2 (n = 434)
Male/female 288/227 (56 %/44 %) 246/187 (57 %/43 %)
Mean/median age (years) 60 (SD 13)/62 (IQR 52–68) 61 (SD 12)/63 (IQR 54–68)
Arrhythmia substrate
Atrial fibrillation 245 (47 %) 214 (49 %)
AVNRT 75 (15 %) 70 (16 %)
Atrial flutter (all) 79 (15 %) 72 (17 %)
Uncommon 10 9




Ventricular extrasystoles/ectopics 12 (2 %) 8 (2 %)
Ventricular tachycardia 12 (2 %) 11 (3 %)
Missing 62 (12 %) 32 (7 %)
Previous intervention
None 188 (36 %) 162 (37 %)
Percutaneous ablation 113 (22 %) 99 (23 %)
Pacemaker fitted 22 (4 %) 16 (4 %)
Coronary angioplasty 6 (1 %) 5 (1 %)
Cardiac surgery 14 (3 %) 13 (3 %)
Other 1 (0 %) 1 (0 %)
Missing 173 (33 %) 138 (32 %)
AVNRT, atrioventricular nodal re-entry tachycardia
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of MCID for all three disease-specific multi-item C-CAP
scales (symptom severity; frequency and duration of symp-
toms; impact on life; Table 6).As such, on an individual level,
the MCID cannot be discriminated from measurement error.
Individuals improving beyond the SDC of 9 points on the
‘‘symptom severity’’ scale, 3 points on the ‘‘frequency and
duration of symptoms scale’’, and 8 points on the ‘‘impact on
life’’ scale can be interpreted as having undergone a minimal
Table 3 Acceptability measures for multi-item and single-item questions within C-CAP1 and C-CAP2
Score mean Missing data Floor/ceiling
effectsa
C-CAP1 (pre-ablation) n = 517
Q1–3b: treatment expectations (4 items; score range 0–16) 4.9 (SD 2.0) 3.5 % 0.6 %/0.2 %
Q4: first ablation procedure (1 item; binary) 71 % (Y); 27 % (N) 1.4 % N/A
Q6: symptom severity index (15 items; score range 0–45) 15.6 (SD 8.6) 16.2 % 1.8 %/0.0 %
Q7–8: frequency and Duration (2 items; score range 0–8) 4.6 (SD 2.0) 3.1 % 7.4 %/9.2 %
Q9: days impact (work/school) (1 item; score range 0–30) 6.1 (SD 10.3) 2.1 %
(65.0 % N/Ab)
52.9 %/12.9 %
Q10: days impact (social activities) (1 item; score range 0–30) 8.6 (SD 10.3) 3.9 %
(34.4 % N/Ab)
27.0 %/12.2 %
Q11: days impact (normal activities) (1 item; score range 0–30) 8.7 (SD 10.4) 4.1 % (30.2 % N/Ab) 26.0 %/13.5 %
Q12a: GP visits in last 30 days (1 item; score range 0–30) 0.6 (SD 1.1) 25.0 % 66.0 %/0 %
Q12b: hospital visits in last 30 days (1 item; score range 0–30) 0.7 (SD 1.0) 22.8 % 58.4 %/0 %
Q13: impact on life (10 items; score range 0–30) 13.8 (SD 7.5) 6.6 % 1.4 %/0.3 %
Q14: medication taken for arrhythmia (1 item; binary) 82 % (Y); 18 % (N) 0.4 % N/A
Q16: importance of reducing medication (1 item; score range 0–3) N/A = 1 %
Not important = 7 %;
Quite
important = 24 %;
Very important = 48 %
19.9 % N/A
EQ-5D-5L (5 items; score range -0.594 to 1.000) 0.7 (SD 0.2) 2.5 % 0.0 %/15.5 %
EQ-VAS (1 item; score range 0–100) 65.2 (SD 18.9) 0.8 % 0.0 %/1.2 %
C-CAP2 (post-ablation) n = 437
Q1–3b: symptom change (4 items; score range 4–16) 8.0 (SD 3.3 %) 5.5 % 15.3 %/2.2 %
Q4: ablation-related complications (1 item; binary) 24 % (Y); 70 % (N) 6.2 % N/A
Q7: expectations met or exceeded (1 item; binary) 68 % (Y); 26 % (N) 6.2 % N/A
Q8: symptom severity index (15 items; score range 0–45) 8.8 (SD 7.8) 16.7 % 8.8 %/0.0 %
Q9–10: frequency and duration (2 items; score range 0–8) 2.6 (SD 2.6) 3.2 % 42.6 %/6.4 %
Q11: days impact (work/school) (1 item; score range 0–30) 5.4 (SD 10.6) 2.7 % (68.4 % N/Ab) 69.8 %/12.7 %
Q12: days impact (social activities) (1 item; score range 0–30) 5.7 (SD 9.6) 4.3 % (47.6 % N/Ab) 52.9 %/9.5 %
Q13: days impact (normal activities) (1 item; score range 0–30) 5.2 (SD 9.1) 5.3 % (45.3 % N/Ab) 53.9 %/8.3 %
Q14a: GP visits in last 30 days (1 item) 0.4 (SD 0.9) 14.6 % 75.1 %/0 %
Q14b: hospital visits in last 30 days (1 item) 0.3 (SD 1.1) 22.9 % 81.6 %/0 %
Q15: impact on life (score range 0–30) 7.2 (SD 7.5) 9.6 % 14.9 %/0.3 %
Q16: medication taken for arrhythmia (1 item; binary) 63 % (Y); 35 % (N) 1.6 % N/A
Q18: medication intake compared with before procedure (1 item;
3 response options)
More = 11 %;
same = 35 %;
less = 17 %
36.4 % N/A
EQ-5D-5L (score range -0.594 to 1.000) 0.8 (SD 0.2) 2.5 % 0.0 %/30.5 %
EQ-VAS (score range 0–100) 72.6 (SD 20.1) 1.1 % 0.0 %/3.9 %
a Lowest/highest scale scores (of respondents)
b Percentage of patients who recorded a response of N/A
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important change. In this sample, participants between 39 and
43 % improved above SDC across the 3 scales.
Discussion
Following incorporation of amendments proposed in this
manuscript through the validation process, the final C-CAP
questionnaires are valid, reliable, and responsive tools for
measuring symptom change in patients undergoing abla-
tion for cardiac arrhythmias (final C-CAP questionnaires
are available as an online resource). The final validated
C-CAP questionnaires (C-CAP1 and C-CAP2) combine
generic global health measures with disease-specific
domains to provide a comprehensive picture of the effect
that arrhythmias have on patients’ lives. This large vali-
dation study builds on previous pilot and content validity
work by our research group [1, 8]. The study has demon-
strated that C-CAP questionnaires can be used on patients
with a range of arrhythmia types and are not limited to
those with AF.
The following amendments have been made to produce
final version of the C-CAP questionnaires (online
resource):
Table 5 Pre-ablation and post-ablation scores and effect size measures in disease-specific scales of C-CAP1 and C-CAP2 and generic scales
Multi-item scale N Mean (SD) ES SRM RE
Pre-ablation Post-ablation Change
C-CAP disease-specific scales shared across C-CAP1 and C-CAP2
Symptom severity (score range 0–45) 318 15.5 (8.3) 8.9 (7.9) -6.6 (8.1)
p\ 0.001
0.80 0.82 6.39
Frequency and duration (score range 0–8) 412 4.7 (2.1) 2.6 (2.6) -2.1 (2.7)
p\ 0.001
1.03 0.78 7.46




EQ-5D-5L (score range -0.594 to 1.00) 416 0.74 (0.22) 0.79 (0.23) 0.05 (0.17)a
p\ 0.001
-0.22 -0.29 1 (Reference)
EQ-VAS (score range 0–100) 426 65.3 (18.8) 72.8 (20.1) 7.4 (17.4)a
p\ 0.001
-0.40 -0.43 2.32
ES, effect size; RE, relative efficiency; SD, standard deviation; SRM, standardised response mean
a Increase in EQ-5D-5L and EQ-VAS indicates an improvement in health status
Table 6 Summary of anchor-based and distribution measures of minimal clinically important difference of three multi-item scales shared across
C-CAP1 and C-CAP2
Mean change score in three disease-specific multi-item C-CAP instruments

















Global health score (EQ-













5.21 5.78 5.93 4.99 5.48 2.80/1.81 7.79/5.02
MCID, minimal clinically important difference; SDC, smallest detectable change; SEM, standard error of measurement
1580 Qual Life Res (2016) 25:1571–1583
123
• Removal of passing out/fainting/blackouts from the
‘‘symptom severity’’ scale and my palpitations have
had a financial impact from the ‘‘impact on life’’ scale
in C-CAP1 (Q13) and C-CAP2 (Q15)
• Removal of the free text section for medication taken
by patients in C-CAP1 (Q15) and C-CAP2 (Q17)
• Amendment of the N/A option for ‘‘days you have
missed at work/school/college’’ to read ‘‘I do not attend
work/school/college (4)’’in C-CAP1 (Q9) and C-CAP2
(Q11)
• Removal of the N/A option from ‘‘days you have had to
cut down on your social activities’’ and ‘‘days you have
been unable to carry out normal daily activities’’
questions in C-CAP1 (Q10–11) and C-CAP2 (Q12–13).
We chose to use a classical test theory approach in our
psychometric analysis, mainly because of our linear model
(pre-/post-testing), our focus on test level scoring, and our
relatively small sample size (\ 500 subjects) at each
measurement point. Further work is being undertaken to
compare pre-ablation C-CAP measures with those col-
lected post-ablation, at 1 and 5 years. Incorporation of
proposed revisions to the C-CAP questionnaires will be
considered for the 5-year follow-up (1-year follow-up uses
the pre-validation questionnaire as the validation work was
not complete at this study point).
The importance of PROMs as tools to drive improve-
ments in service provision is well recognised [5]. Through
future research and use in routine practice, the C-CAP
questionnaires provide a tool for UK clinicians and com-
missioners to collect evidence on whether provision of a
cardiac ablation service is having a positive impact on
patients which may be difficult to demonstrate through
other means. C-CAP has the advantage of enabling com-
parison of outcomes across different arrhythmia groups,
and inclusion of the generic EQ-5D-5L tool allows for
wider cross-speciality comparisons [10]. With appropriate
further translation and validation work, the C-CAP tool
could be used outside of the UK.
The influence of patient expectations on their treatment
and recovery has been widely demonstrated [17]. A novel
section has been included in C-CAP1 enabling clinicians to
explore and manage patient expectations. Appropriate
expectation management may improve overall satisfaction
with the service. Future analysis will provide an insight
into how patient expectations influence the perception of
procedural success.
High response rates for C-CAP1 and C-CAP2 indicate
that patients find the questionnaires acceptable and that
they are not overly burdensome. We identified issues with
high numbers of responses to the not applicable option for
questions of ‘‘number of days impacted’’. We suspect that
some are valid responses but that a proportion may be
unreliable. Also the free text format questions relating to
medication intake were difficult to validate in any mean-
ingful way. The original purpose was to use a medication
dose question to explore changes following ablation;
however, a lack of consistency in patients’ responses
coupled with the challenges of extrapolating changes in
medication regimes as better or worse led us to conclude
that this question provided limited value.
Ceiling/floor effects are considered to be an issue if
15 % of patients report maximum and minimum scores
[12, 18], and were observed in the ‘‘frequency and duration
of symptoms’’; this may be due in part to patients experi-
encing a true alleviation of symptoms and also a function
of fewer items within the scale. Test–retest reliability was
impressive across individual questions and scales and high
internal consistency measures were observed. Removal of
some items improved the Cronbach’s alpha values.
Disease-specific multi-item C-CAP scales (shared across
C-CAP1 and C-CAP2) ‘‘symptom severity’’ and ‘‘impact
on life’’ were more responsive to changes following abla-
tion than the global health measures of EQ-5D-5L and EQ-
VAS, shown by much larger effect sizes. We have pre-
sented distribution-based and anchor-based estimates of
MCID alongside SDC values to aid interpretability of
quantitative scores. Anchor-based MCIDs are variable
because the MCID depends on the definition of ‘‘important
difference’’ in the global measure [19]. Several threshold
values for SEM have been suggested to estimate MCID;
some assert that 1 SEM is roughly equivalent to the min-
imal important difference determined using anchor-based
methods, and others prefer 1.96*SEM [14]. Our results
demonstrated that 1.96*SEM came close to the anchor-
based method of MCID estimation.
The disadvantage of anchor-based methods is that they
do not take into account the measurement precision of the
instrument, and alone cannot tell us whether the MCID lies
within the measurement error [14]. This study indicated
that the SDC is higher than the MCID across three disease-
specific C-CAP multi-item scales (symptom severity; fre-
quency and duration of symptoms; impact on life). The
study by Lin et al. [20] states that in some instances the
MCID scores do not exceed the SDC scores but still con-
vey information about whether a patient group experienced
a clinically important change. A 9 point change on the
‘‘symptom severity’’ scale indicates a true and reliable
improvement, but a 6–7 point change may be considered
clinically meaningful to the patient. The MCID cannot be
used to define an important deterioration because we only
analysed improved patients and caution should be applied
with low baseline scores.
As well as the observation that SDC is higher than the
MCID in the disease-specific scales, there were several
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methodological limitations in this study. Anchor questions
were not prospectively designed and included to calculate
MCID, although those questions provided adequate proxies
for the definition of minimal improvement. Known-groups
validity could have been explored in patients for whom
their arrhythmia symptoms are adequately controlled by
medication. Convergent validity would have been better
evaluated by testing another validated AF questionnaire [6]
which we would assume measures a similar construct.
Future research should test the structure of the C-CAP
questionnaires using confirmatory analysis.
The results of this validation study show that the final
C-CAP questionnaires (online resource) can be used reli-
ably to measure changes in arrhythmia-related symptom
severity, symptom frequency and duration, and impact on
life before and after percutaneous cardiac ablation. Addi-
tional domains of patient expectations and complications
can also be reliably explored using C-CAP1 and C-CAP2.
We encourage researchers and clinicians to use C-CAP
questionnaires in research and routine clinical settings to
measure the impact of ablation services on patients’ QoL
(final questionnaires are provided as an Online Resource,
copyright Cedar).
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